Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

BACKGROUND: To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer. METHODS: Vandetanib (an orally bioavailable VEGFR-2 and EGFR tyrosine kinases inhibitor) was combined at...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyerhardt, Jeffrey A., Ancukiewicz, Marek, Abrams, Thomas A., Schrag, Deborah, Enzinger, Peter C., Chan, Jennifer A., Kulke, Matthew H., Wolpin, Brian M., Goldstein, Michael, Blaszkowsky, Lawrence, Zhu, Andrew X., Elliott, Meaghan, Regan, Eileen, Jain, Rakesh K., Duda, Dan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373492/
https://www.ncbi.nlm.nih.gov/pubmed/22701615
http://dx.doi.org/10.1371/journal.pone.0038231

Ejemplares similares

Ejemplares similares